Pharmaids Pharmaceuticals Share Price

Pharmaids Pharmaceuticals Investment Rating

• Master Rating:

• Pharmaids Pharms. has an operating revenue of Rs. 3.94 Cr. on a trailing 12-month basis. An annual revenue de-growth of -54% needs improvement, Pre-tax margin of 4% needs improvement, ROE of 1% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It has recently broken out of a base in its weekly chart and is trading around 21% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 6 which is a POOR score indicating inconsistency in earnings, a RS Rating of 78 which is FAIR indicating the recent price performance, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 124 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.